Dr. Martin presented about the MonarchE study. In the MonarchE study, there are patients who have received neoadjuvant chemotherapy. They evaluated the Ki67 index before neoadjuvant chemotherapy and after neoadjuvant chemotherapy. They found that the change between pre and post-treatment in terms of Ki67 has a very good prognostic factor which can predict the patient prognosis, especially the Ki67 high to high patient, low to low patient...
Dr. Martin presented about the MonarchE study. In the MonarchE study, there are patients who have received neoadjuvant chemotherapy. They evaluated the Ki67 index before neoadjuvant chemotherapy and after neoadjuvant chemotherapy. They found that the change between pre and post-treatment in terms of Ki67 has a very good prognostic factor which can predict the patient prognosis, especially the Ki67 high to high patient, low to low patient. So these are very separate, very much in terms of the prognosis and there is a high to low patient in that case I’ve made a note, 0.35, so it seems it might be by chance but it might be much more than other patterns, but anyway, as a result, Ki67 between the neurological and chemistry before and after can predict the patient’s prognosis more precisely, and the adjuvant therapy works in any kind of situation, so this is not an efficacy predictive archetype.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
